Pc.6 Acupressure for Dental Nausea: A Prospective Randomised Double Blind Clinical Trial with Crossover, Part 2

1998 ◽  
Vol 16 (2) ◽  
pp. 69-72 ◽  
Author(s):  
RAC Chate
Keyword(s):  
Clinical Trial ◽  
Selection Criterion ◽  
Initial Point ◽  
First Trimester ◽  
Small Sample ◽  
Double Blind ◽  
Double Blind Clinical Trial ◽  
The Mean ◽  
The Difference ◽  
Prior Application

This reports the second part of a single-centre, prospective, randomised, double-blind clinical trial with crossover. It has aimed to assess whether PC.6 acupressure could reduce nausea related to maxillary dental impression taking. The selection criterion was a self registration of nausea greater than 33% of a 100mm visual analogue scale (VAS) following an initial maxillary impression (control) in patients referred for treatment. Exclusion criteria were: current medication with a secondary emetic or anti-emetic effect, prior knowledge of PC.6 acupressure, a recent history of nausea, and the first trimester of pregnancy. Twenty three entered the trial and 18 completed. The test involved a second and third impression with prior application of finger pressure on either PC.6 or a dummy point on the forearm The initial point was chosen by the patient, leaving the other point to be pressed subsequent to crossover. The mean level of nausea was recorded by patients after PC.6 acupressure and also after pressure at a dummy point. These recordings were then compared. The sample consisted of 6 males and 12 females, and the mean age was 14.74 years. The mean difference in nausea between PC.6 acupressure and pressure at the dummy point was −0.39mm % of the VAS (SD 40.48mm %). The 95% Confidence Interval was −20.52 and 19.74mm %, and the difference was not significant. Three and a half minutes of PC.6 acupressure did not significantly reduce nausea experienced with a maxillary impression, compared with pressure at the dummy point, in this small sample: both showed a mean reduction of 50% on the control figure.

Pc.6 Acupressure for Dental Nausea: A Preliminary Report of a Prospective Randomised Double Blind Clinical Trial, Part 1

1997 ◽  
Vol 15 (1) ◽  
pp. 6-9 ◽  
Author(s):  
RAC Chate
Keyword(s):  
First Trimester ◽  
Small Sample ◽  
Cytotoxic Agents ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Clinical Trial ◽  
First Trimester Of Pregnancy ◽  
The Difference ◽  
Prior Application ◽  
Randomised Controlled

Acupressure effectively reduces the amount of nausea experienced, both in the first trimester of pregnancy, and after either opiates or cytotoxic agents. The aim of this randomised, controlled study was to establish whether it could also reduce any sensation of nausea related to the taking of maxillary dental impressions. The sample comprised 8 males and 14 females, with a mean age of 14.64 years and whose self-registration of nausea following an impression was greater than 33% of a 100mm visual analogue. The test involved a second impression with prior application of pressure on either PC.6, the sixth point on the Chinese pericardial meridian, or a placebo point on the forearm of the patient's dominant limb. A random mental choice as to which point to press was made by each patient, and double blind conditions prevailed. After the withdrawal of the impression, another visual analogue was marked. Of the 9 patients who had used the placebo point during the test impression, there had been a mean reduction of 29% in the scale of nausea experienced. Of the 13 who had used the PC.6 acupressure point, the mean reduction was 30%. The difference was not significant. Three and a half minutes of acupressure on PC.6 did not reduce the sensation of nausea induced by tactile stimulation of the soft palate in this small sample of susceptible patients.

scholarly journals Comparing the Efficacy of Topical Metformin and Placebo in the Treatment of Melasma: A Randomized, Double-blind, Clinical Trial

2019 ◽  
pp. 1-8
Author(s):  
Mohammad Ali Mapar ◽  
Ali Asghar Hemmati ◽  
Ghazal Namdari
Keyword(s):  
Clinical Trial ◽  
Placebo Group ◽  
Double Blind ◽  
Laboratory Findings ◽  
Double Blind Clinical Trial ◽  
Metformin Group ◽  
Significant Difference ◽  
Before And After ◽  
P 16 ◽  
The Mean

Introduction: Generally affecting women, melasma is the acquired disorder of hyperpigmentation, and researches are still ongoing to find an effective, fast, and low-side-effect drug treating this disease. The present study is aimed at comparing the efficacy of topical metformin and placebo in the treatment of melasma. Methods: Sixty patients with melasma were treated in placebo and topical metformin recipient groups in a double-blind clinical trial. In addition to the demographic and laboratory findings of patients before and after the intervention, the MASI Score of patients in weeks 0, 4, 8, and 12 of the study and then one month after the study were analyzed using SPSS version 20 software. Results: The mean age of the studied patients was 35.25 ± 7.11 years. No significant difference was observed between the phenotypes (P= .49) and the type of melasma (P= .63) in the two groups. The mean MASI score of patients at the time of being included in the study in the placebo group was 10.47 ± 3.08; and in the metformin group, it was 11.93 ± 4.64 (P = .16). Compared to the beginning of the study, the MASI scores were significantly decreased in both groups of placebo (P = .00) and metformin (P = .00) one month after the end of the study; nevertheless, no statistically significant difference was observed between the MASI Scores of two groups in any of the study periods (P > .05). Conclusion: The results of the present study showed that metformin cream significantly declines the patients’ MASI score and does not have any effect on patients’ laboratory markers. Of course, no significant difference was observed between the MASI scores of the patients receiving metformin and the placebo group; however, the MASI score decrease trend continued until the 12th week; while in the placebo group, no significant decrease was seen after eight weeks.

Comparison of the Analgesic Effect of Intravenous Ketamine versus Intravenous Morphine in Reducing Pain of Renal Colic Patients: Double-Blind Clinical Trial Study

2019 ◽  
Vol 14 (4) ◽  
pp. 280-285 ◽  
Author(s):  
Arash Forouzan ◽  
Kambiz Masoumi ◽  
Hassan Motamed ◽  
Seyed Reza Naji Esfahani ◽  
Ali Delirrooyfard
Keyword(s):  
Clinical Trial ◽  
Renal Colic ◽  
Initial Result ◽  
Double Blind ◽  
Double Blind Clinical Trial ◽  
Significant Difference ◽  
Intravenous Morphine ◽  
Hospital Patients ◽  
The Mean ◽  
Intravenous Ketamine

Background: The effective relief of renal colic patients with low complications is one of the important concerns of emergency physicians. The aim of this study was to investigate the use of injectable ketamine as an alternative to routine drugs in the relief of pain in patients with renal colic. Methods: This double-blind clinical trial was conducted on patients who had suffered kidney pain due to kidney stones in 2017, referred to Ahvaz Imam Khomeini Hospital. Patients were divided into 2 groups: the first group received intravenous ketamine (0.3 mg/kg) and the second group received intravenous morphine (0.1 mg/kg) in a double-blind form. Finally, the mean pain was evaluated before injection, after 10, 20, 30, and 60 minutes as the initial result while the side effects were considered as secondary results. Results: In this study, 135 patients with renal colic participate in this study. The mean pain at the time of referral to the hospital in the group receiving morphine and ketamine was 9.2 and 9.2, respectively, which did not show any significant difference. Based on these findings, there was no significant difference between the factors evaluated during the study of the two groups. Only in the ketamine group, there were 3 cases of nausea and 1 of vomiting. However, there was a significant increase in the need for additional doses of fentanyl in the morphine recipient group (p = 0.02). Conclusion: The findings suggest that the use of ketamine can produce a more rapid relief effect, and decrease the use of opioids which create various complications, including nausea and vomiting in patients, especially patients with renal colic.

scholarly journals Mig-RL: a Natural Preventive Treatment Against Migraine. Outcomes of a Randomized, Double-Blind Clinical Trial

2021 ◽  
Vol 8 (7) ◽  
pp. 01-09
Author(s):  
Rémi Shrivastava
Keyword(s):  
Clinical Trial ◽  
Side Effects ◽  
Plant Extracts ◽  
Preventive Treatment ◽  
Episodic Migraine ◽  
Salix Alba ◽  
Double Blind ◽  
Tanacetum Parthenium ◽  
Double Blind Clinical Trial ◽  
The Mean

BACKGROUND The efficacy and safety of Mig-RL (Commercial name HERBA MIG), a synergistic association of two plant extracts, Tanacetum parthenium (150mg, 0.5% parthenolide) and Salix Alba (150mg, 25% salicin) were investigated as a preventive treatment for episodic migraine. Mig-RL was compared with a placebo in a randomized, double-blind clinical trial. MATERIALS AND METHODS This trial included 129 patients having episodic migraine and diagnosed with migraines without aura for over a year and meeting the migraine criteria, as defined in the International Classification of Headache Disorder (ICHD-3 :1.1). P). Baseline data was collected for 28 days before the start of the three-months treatment period. Patients were randomized in a 1:1 ratio to receive either Mig-RL (a single dose of 300mg per day, per os) or placebo (identical capsules containing 300 mg starch, 1 per day, per os) for a period of 12 consecutive weeks. The primary endpoint was the mean change in the average number of migraine days per month, comparing the baseline 28-days pre-intervention period with the weeks 9 to 12 after the first dose of the trial regimen. Secondary endpoints were the percentage of patients with a reduction of at least 30% in the average number of migraine days per month and days of use of any acute headache medication per month. The HIT-6 and MIDAS scores were also evaluated vs. baseline between the two groups. RESULTS Out of 172 patients enrolled, 129 were randomly assigned to the Mig-RL arm (n=65) or the placebo arm (n=64). The mean (±SD) number of baseline migraine days per month was 8.4±1.9 and 8.7±1.9, respectively. The mean reduction in the average number of migraine days per month was 2.5±0.4 (p<0.001) with Mig-RL and 1.9±0.4 (p<0.001) with placebo. A difference of 0.6±0.4 (p=0.01) between the two groups. The percentage of patients with at least 30% reduction in average number of migraine days per month was 49% in Mig-RL and 32% in placebo (p<0.05 vs. placebo). Only a few isolated and minor side effects were reported and overall Mig-RL was well tolerated by patients. CONCLUSIONS Mig-RL, a synergistic combination of two plant extracts, seems to have a moderate effect in the prevention of migraines. Without side effects, the combination of Tanacetum parthenium and Salix alba could be an additional help for some patients. However, further investigations and an improvement in the quality of the plants are still necessary.

Effect of Topical Anesthesia with Lidocaine-prilocaine (EMLA) Cream and Local Pressure on Pain during Infiltration Injection for Maxillary Canines: A Randomized Double-blind Clinical Trial

2016 ◽  
Vol 17 (7) ◽  
pp. 592-596 ◽  
Author(s):  
Amin S Milani ◽  
Vahid Zand ◽  
Amir A Abdollahi ◽  
Mohammad Froughreyhani ◽  
Parvin Zakeri-Milani ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Topical Anesthesia ◽  
Injection Pain ◽  
Local Pressure ◽  
Double Blind ◽  
Emla Cream ◽  
Double Blind Clinical Trial ◽  
The Difference ◽  
Lidocaine Prilocaine ◽  
Finger Pressure

ABSTRACT Objectives This study compared the effect of local pressure and topical lidocaine-prilocaine (EMLA) cream on pain during infiltration injection for maxillary canine teeth. Materials and methods A total of 140 volunteer students participated in this split-mouth design randomized clinical trial. The subjects were randomly divided into four groups (n = 35). Before administration of anesthesia, in each group, one side was randomly selected as the experimental and the opposite side as the control. In group 1, finger pressure was applied on the alveolar mucosa on the experimental side and on the tooth crown on the control side. In group 2, 5% EMLA cream and placebo; in group 3, finger pressure and 5% EMLA cream; and in group 4, 5% EMLA cream and 20% benzocaine gel were applied. In all the groups, a buccal infiltration procedure was carried out. Pain during injection was recorded with visual analog scale (VAS). Wilcoxon and McNemar tests were used for statistical analysis of the results. Statistical significance was set at p < 0.05. Results The results showed that EMLA reduced the injection pain significantly more than benzocaine (p = 0.02). Also, injection pain was significantly lower with the use of EMLA in comparison to placebo (p = 0.00). Application of local pressure reduced the injection pain, but the difference from the control side was not significant (p = 0.05). Furthermore, the difference between application of local pressure and EMLA was not statistically significant (p = 0.08). Conclusion Topical anesthesia of 5% EMLA was more effective than 20% benzocaine in reducing pain severity during infiltration injection. However, it was not significantly different in comparison to the application of local pressure. How to cite this article Milani AS, Zand V, Abdollahi AA, Froughreyhani M, Zakeri-Milani P, Jafarabadi MA. Effect of Topical Anesthesia with Lidocaine-prilocaine (EMLA) Cream and Local Pressure on Pain during Infiltration Injection for Maxillary Canines: A Randomized Double-blind Clinical Trial. J Contemp Dent Pract 2016;17(7):592-596.

scholarly journals Effects of Iron Supplementation on Hemoglobin Concentration in 12-18 Month Old Iron-Deficient Anemic Infants

2018 ◽  
Vol 34 (7-8) ◽  
pp. 179-86
Author(s):  
Iskandar Iskandar ◽  
Nono Sumarna Afandi ◽  
Ponpon Ijradinata
Keyword(s):  
Clinical Trial ◽  
Ferrous Sulfate ◽  
Iron Supplementation ◽  
Hemoglobin Concentration ◽  
Double Blind ◽  
Similar Treatment ◽  
Double Blind Clinical Trial ◽  
Iron Deficient ◽  
The Mean ◽  
Treatment Randomization

A randomized double blind clinical trial was conducted to study the effects of iron supplementation on hemoglobin values of 97 iron-deficient anemic (DA) and iron-sufficient (IS) infants, 12 to 18 months of age. IDA (n=SO) infants were assigned randomly to either receive dietary ferrous sulfate or placebo for 4 months. Similar treatment randomization was done among IS (n=4 7) infants. Before intervention, the mean hemoglobin value of the IDA infants was significantly (p<0.01) lower than that of the IS group. After intervention, there was an increase in the hemoglobin values of the IDA infants who had received iron, and was significantly (p<0.01) higher than those of the placebo treated IDA group, lS group, as well as placebo treated IS group. Hemoglobin values of the IDA infants who had received iron, increased up to the normal level as refer to the WHO's criteria used for normal hemoglobin values.

Sign in / Sign up

Export Citation Format

Share Document